Circulating MicroRNAs as Clinical Biomarkers in the Predictions of Pregnancy Complications

Predicting pregnancy complications is a major topic for clinicians and biologists for maternal and fetal monitoring. Noninvasive biomarkers in maternal blood such as circulating microRNAs (miRNAs) are promising molecules to predict pregnancy disorders. miRNAs are noncoding short RNAs that regulate mRNA expression by repressing the translation or cleaving the transcript. miRNAs are released to the extracellular systemic circulation via exosomes. The discovery of plasma- or serum-derived miRNAs and of free-circulating exosomes that contain miRNAs provides useful information about the physiological or pathophysiological roles of the miRNAs. Specific placental miRNAs are present in maternal plasma in different ways depending on whether the pregnancy is normal or pathological or if there is no pregnancy. This paper focuses on placental miRNAs and extracellular miRNAs to the placenta whose misregulation could lead to pregnancy complications

Circulating MicroRNAs as Clinical Biomarkers in the Predictions of Pregnancy Complications

Predicting pregnancy complications is a major topic for clinicians and biologists for maternal and fetal monitoring. Noninvasive biomarkers in maternal blood such as circulating microRNAs (miRNAs) are promising molecules to predict pregnancy disorders. miRNAs are noncoding short RNAs that regulate mRNA expression by repressing the translation or cleaving the transcript. miRNAs are released to the extracellular systemic circulation via exosomes. The discovery of plasma-or serum-derived miRNAs and of free-circulating exosomes that contain miRNAs provides useful information about the physiological or pathophysiological roles of the miRNAs. Specific placental miRNAs are present in maternal plasma in different ways depending on whether the pregnancy is normal or pathological or if there is no pregnancy. This paper focuses on placental miRNAs and extracellular miRNAs to the placenta whose misregulation could lead to pregnancy complications

The ACES mission: System development and test status

Atomic Clock Ensemble in Space (ACES) is an ESA mission in fundamental physics based on a new generation of clocks operated in the microgravity environment of the International Space Station. Installed at the external payload facility of the Columbus module, ACES will accommodate two atomic clocks: PHARAO, a primary frequency standard based on samples of laser cooled Cs atoms, and the active H-maser SHM. The two on-board clocks will generate a time scale with fractional frequency instability and inaccuracy of a few parts in 1016. The ACES frequency reference will be distributed to ground by a MicroWave Link (MWL) and used to compare distant clocks. These comparisons will allow precision tests of the Einstein's theory of general relativity, including a measurement of the gravitational red-shift, a search for time variations of fundamental constants, and tests of the standard model extension. ACES will also support applications in different areas of research, including geodesy and GNSS remote sensing. A link in the optical domain is also part of ACES for time transfer experiments, ranging, and analysis of atmospheric propagation delays. The engineering models of the ACES clocks and main subsystems have been successfully tested, and manufacturing of the flight models has been started. Mission concept, scientific objectives, and status of ACES will be presented together with the latest test results

Antidepressive effects of targeting ELK-1 signal transduction

International audienceDepression, a devastating psychiatric disorder, is a leadingcause of disability worldwide. Current antidepressants addressspecific symptoms of the disease, but there is vast roomfor improvement1. In this respect, new compounds that actbeyond classical antidepressants to target signal transductionpathways governing synaptic plasticity and cellular resilienceare highly warranted2–4. The extracellular signal–regulatedkinase (ERK) pathway is implicated in mood regulation5–7, butits pleiotropic functions and lack of target specificity prohibitoptimal drug development. Here, we identified the transcriptionfactor ELK-1, an ERK downstream partner8, as a specificsignaling module in the pathophysiology and treatment ofdepression that can be targeted independently of ERK. ELK1mRNA was upregulated in postmortem hippocampal tissuesfrom depressed suicides; in blood samples from depressedindividuals, failure to reduce ELK1 expression was associatedwith resistance to treatment. In mice, hippocampal ELK-1 overexpressionper se produced depressive behaviors; conversely,the selective inhibition of ELK-1 activation prevented depression-like molecular, plasticity and behavioral states inducedby stress. Our work stresses the importance of target selectivityfor a successful approach for signal-transduction-basedantidepressants, singles out ELK-1 as a depression-relevanttransducer downstream of ERK and brings proof-of-conceptevidence for the druggability of ELK-1